Therapeutic safety and effectiveness of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patients with renal dysfunction

Motoyuki Kohjima, Kenta Motomura, Toshimasa Koyanagi, Seiya Tada, Naoki Yamashita, Takeaki Sato, Syoji Nagase, Masaki Kato, Kazuhiro Kotoh, Makoto Nakamuta

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

We investigated the safety and effectiveness of the dual oral therapy with Daclatasvir (DCV) and Asunaprevir (ASV) for patients with renal dysfunctioa This study enrolled 682 HCV genotype lb patients treated with DCV and ASV and included 83 patients with eGFR less than 50 m//min/1.73 m2, and 17 patients with eGFR less than 30 m//min/L73 m2. Serum creatinine and eGFR were not altered during the treatment and the rate of complications and viral response was similar between patients with renal dysfunction and patients without renal dysfunction. The treatment with DCV and ASV was well tolerated and safety enough even for the HCV patients with renal dysfunction and could be productive therapeutic option for aged patients that accounts many of patients with HCV genotype lb infection in Japan.

元の言語英語
ページ(範囲)142-145
ページ数4
ジャーナルActa Hepatologica Japonica
57
発行部数3
DOI
出版物ステータス出版済み - 4 8 2016

Fingerprint

Kidney
Safety
Therapeutics
Genotype
BMS-790052
asunaprevir
Creatinine
Japan
Infection
Serum

All Science Journal Classification (ASJC) codes

  • Hepatology

これを引用

Therapeutic safety and effectiveness of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patients with renal dysfunction. / Kohjima, Motoyuki; Motomura, Kenta; Koyanagi, Toshimasa; Tada, Seiya; Yamashita, Naoki; Sato, Takeaki; Nagase, Syoji; Kato, Masaki; Kotoh, Kazuhiro; Nakamuta, Makoto.

:: Acta Hepatologica Japonica, 巻 57, 番号 3, 08.04.2016, p. 142-145.

研究成果: ジャーナルへの寄稿記事

Kohjima, Motoyuki ; Motomura, Kenta ; Koyanagi, Toshimasa ; Tada, Seiya ; Yamashita, Naoki ; Sato, Takeaki ; Nagase, Syoji ; Kato, Masaki ; Kotoh, Kazuhiro ; Nakamuta, Makoto. / Therapeutic safety and effectiveness of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patients with renal dysfunction. :: Acta Hepatologica Japonica. 2016 ; 巻 57, 番号 3. pp. 142-145.
@article{f3f38f4824d14e2da55dc9de64eb4c74,
title = "Therapeutic safety and effectiveness of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patients with renal dysfunction",
abstract = "We investigated the safety and effectiveness of the dual oral therapy with Daclatasvir (DCV) and Asunaprevir (ASV) for patients with renal dysfunctioa This study enrolled 682 HCV genotype lb patients treated with DCV and ASV and included 83 patients with eGFR less than 50 m//min/1.73 m2, and 17 patients with eGFR less than 30 m//min/L73 m2. Serum creatinine and eGFR were not altered during the treatment and the rate of complications and viral response was similar between patients with renal dysfunction and patients without renal dysfunction. The treatment with DCV and ASV was well tolerated and safety enough even for the HCV patients with renal dysfunction and could be productive therapeutic option for aged patients that accounts many of patients with HCV genotype lb infection in Japan.",
author = "Motoyuki Kohjima and Kenta Motomura and Toshimasa Koyanagi and Seiya Tada and Naoki Yamashita and Takeaki Sato and Syoji Nagase and Masaki Kato and Kazuhiro Kotoh and Makoto Nakamuta",
year = "2016",
month = "4",
day = "8",
doi = "10.2957/kanzo.57.142",
language = "English",
volume = "57",
pages = "142--145",
journal = "Acta Hepatologica Japonica",
issn = "0451-4203",
publisher = "Japan Society of Hepatology",
number = "3",

}

TY - JOUR

T1 - Therapeutic safety and effectiveness of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patients with renal dysfunction

AU - Kohjima, Motoyuki

AU - Motomura, Kenta

AU - Koyanagi, Toshimasa

AU - Tada, Seiya

AU - Yamashita, Naoki

AU - Sato, Takeaki

AU - Nagase, Syoji

AU - Kato, Masaki

AU - Kotoh, Kazuhiro

AU - Nakamuta, Makoto

PY - 2016/4/8

Y1 - 2016/4/8

N2 - We investigated the safety and effectiveness of the dual oral therapy with Daclatasvir (DCV) and Asunaprevir (ASV) for patients with renal dysfunctioa This study enrolled 682 HCV genotype lb patients treated with DCV and ASV and included 83 patients with eGFR less than 50 m//min/1.73 m2, and 17 patients with eGFR less than 30 m//min/L73 m2. Serum creatinine and eGFR were not altered during the treatment and the rate of complications and viral response was similar between patients with renal dysfunction and patients without renal dysfunction. The treatment with DCV and ASV was well tolerated and safety enough even for the HCV patients with renal dysfunction and could be productive therapeutic option for aged patients that accounts many of patients with HCV genotype lb infection in Japan.

AB - We investigated the safety and effectiveness of the dual oral therapy with Daclatasvir (DCV) and Asunaprevir (ASV) for patients with renal dysfunctioa This study enrolled 682 HCV genotype lb patients treated with DCV and ASV and included 83 patients with eGFR less than 50 m//min/1.73 m2, and 17 patients with eGFR less than 30 m//min/L73 m2. Serum creatinine and eGFR were not altered during the treatment and the rate of complications and viral response was similar between patients with renal dysfunction and patients without renal dysfunction. The treatment with DCV and ASV was well tolerated and safety enough even for the HCV patients with renal dysfunction and could be productive therapeutic option for aged patients that accounts many of patients with HCV genotype lb infection in Japan.

UR - http://www.scopus.com/inward/record.url?scp=84963660237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963660237&partnerID=8YFLogxK

U2 - 10.2957/kanzo.57.142

DO - 10.2957/kanzo.57.142

M3 - Article

VL - 57

SP - 142

EP - 145

JO - Acta Hepatologica Japonica

JF - Acta Hepatologica Japonica

SN - 0451-4203

IS - 3

ER -